Vibeke Vergote

7PUBLICATIONS
45CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Metabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|Mar 23, 2026
Masquerading as an Interstitial Lung Disease: Intravascular Large B-Cell Lymphoma With Prominent Neo-Angiogenesis.

Andreas Lancelot, Anne-Marie Delsupehe, Vibeke K J Vergote

|Oct 22, 2025
Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Giulia Magno, Kai Rejeski, Giulia Rappa

|Jun 15, 2025
Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis.

Vibeke K J Vergote, Gregor Verhoef, Ann Janssens

|Oct 17, 2024
Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven.

Jan Brijs, Jonas Van Ham, Benedicte Dubois

|Oct 12, 2022
[18F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma.

Vibeke K J Vergote, Gregor Verhoef, Ann Janssens

Pageof 2

Frequent Collaborators

3 joint publications

Jonas Van Ham

2 joint publications

Peter Vandenberghe

2 joint publications

Daan Dierickx

2 joint publications

Jan Brijs